Spend time with your patients, discussing both the risks and benefits of a potential coronavirus disease 2019 vaccine, emphasized Maura Abbott, PhD, AOCNP, CPNP, RN, assistant professor of nursing at the Columbia University School of Nursing.
Spend time with your patients, discussing both the risks and benefits of a potential coronavirus disease (COVID) 2019 vaccine; talk with them about their fears; and perhaps most important, be patient and transparent, emphasized Maura Abbott, PhD, AOCNP, CPNP, RN, assistant professor of nursing at the Columbia University School of Nursing.
Transcript
What can be said to assuage the fears people have about a coronavirus vaccine?
I think many of these fears are very common about any sort of clinical trial, whether it be a COVID vaccine or even trials for new cancer therapies. I think people inherently have fears, because it's a clinical trial and something that's new. And so I think what we can say as health care providers to assuage our patients’ fears is just basically to spend the time answering their questions, provide as much transparent information as we have, as possible, about the process of development, about the potential side effects.
And I think, again, we just need to be patient with people, as they're able to state their fears and we're able to answer their questions and patiently work with them very transparently, and at the level that they understand. Don't talk above their heads. Tell them exactly what's going on.
Talking about risks and benefits is another really important part of this. As you mentioned, there are definitely people that are disproportionately affected, and persons of color, and I think that's something that we should discuss with our patients when applicable.
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More